.avif)
DR Reddy Laboratories Email Format
Pharmaceutical Manufacturing
・
10,001-25,000 employees
・
Hyderabad, Telangana, India
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India, providing APIs, generics, biosimilars, and OTC products across major markets worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@drreddys.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1984
Headquarters
Hyderabad, Telangana, India
Revenue
$2.5B-$5B
FUNDING Stage
Public
Website
Key Executives
Erez Israeli (Chief Executive Officer), M V Narasimham (Chief Financial Officer), Sanjay Sharma (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of DR Reddy Laboratories?
DR Reddy Laboratories uses the firstinitiallast format, so Jane Smith would be jsmith@drreddys.com.
What are the main business segments that DR Reddy Laboratories operates across?
DR Reddy Laboratories operates across four core segments: Generics, API and Services, Innovative Medicines, and Consumer Health. The Generics segment, which covers the US and Canada, is the company's largest revenue driver. Tools like Clay can help you find contacts across each of these divisions.
How many employees does DR Reddy Laboratories have in 2026?
DR Reddy Laboratories employs approximately 32,182 people globally, with its headquarters in Hyderabad, Telangana, India and major operations spanning North America, Europe, and other markets.
Who leads DR Reddy Laboratories as CEO in 2026?
Erez Israeli serves as the Chief Executive Officer of DR Reddy Laboratories in 2026. He is supported by M V Narasimham as Chief Financial Officer and Sanjay Sharma as Chief Operating Officer.
Which new markets did DR Reddy Laboratories enter with its generic Semaglutide launch in 2026?
In May 2026, DR Reddy Laboratories launched its generic Semaglutide Injection in Canada, making Canada the first G7 country to grant market authorization for the product and marking a significant expansion of DR Reddy Laboratories' GLP-1 portfolio internationally.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating